DF13BB1
Brachytherapy Pancreas to Unidirectional Source with Palladium 103 (Pd-103), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | F Hepatobiliary System and Pancreas |
| Operation | 1 Brachytherapy |
| Body Part | 3 Pancreas |
| Approach | B Low Dose Rate (LDR) |
| Device | B Palladium 103 (Pd-103) |
| Qualifier | 1 Unidirectional Source |
Procedure Overview
Brachytherapy to the hepatobiliary system and pancreas involves placing a radioactive source directly within or immediately adjacent to the liver, bile ducts, gallbladder, or pancreas, allowing a high dose to reach the tumor while limiting exposure to the rest of the organ and surrounding structures. This localized approach is often chosen when a tumor is close to the bowel or other radiation-sensitive tissue, where external beams alone could cause more collateral damage. It may be used on its own or combined with other cancer treatments depending on the extent of disease.
Delivery usually involves a catheter, needle, or radioactive bead placed through an interventional or minimally invasive approach, sometimes guided by imaging or performed at the time of another procedure. The source may remain in place briefly for a single treatment session or, in some techniques, be left permanently in very low-dose form. Patients are monitored afterward for signs of bleeding, infection, or irritation at the treated organ.
Anatomy & Axis Detail
Pancreas
The pancreas is a retroperitoneal gland that produces digestive enzymes and hormones including insulin, and pancreatic adenocarcinoma is notoriously difficult to treat surgically because the organ sits deep in the abdomen and wraps around major vessels such as the superior mesenteric artery and portal vein. Brachytherapy for pancreatic tumors involves implanting radioactive seeds or an applicator directly into or against the tumor, most often during an open surgical procedure when the mass is found to be unresectable or when margins are close, delivering a concentrated dose to the gland itself while limiting exposure to the adjacent bowel, stomach, and vasculature that surround it. Careful placement and image confirmation are essential given how tightly packed the surrounding anatomy is.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Palladium 103 (Pd-103)
Palladium-103 is another low-dose-rate isotope used in permanent interstitial seed implants, chiefly for prostate brachytherapy, but its shorter half-life (about 17 days) delivers its therapeutic dose faster than I-125. Clinicians may favor it for higher-grade or faster-growing tumors where a more concentrated early dose is desired, while I-125 remains preferred for lower-risk, slower disease.
Qualifier: Unidirectional Source
This qualifier specifies that a unidirectional radioactive source is used in radiation therapy, meaning the source emits radiation in one direction rather than uniformly, as with certain brachytherapy applicators. It distinguishes this directional delivery technique from standard radiation sources, which do not require this added qualifying detail.
Coding & Documentation
The physician's note must document that a radioactive source was physically placed in or next to the hepatobiliary or pancreatic tissue, along with the approach used to get it there, since this determines the qualifier assigned. Coders should verify the exact organ treated, distinguishing the liver from the bile ducts, gallbladder, and pancreas, because each is a separate body part value in this table. A frequent error is coding this family when the documentation actually describes microsphere embolization or a similar interventional technique without a formal radiation source designation, which requires clarification with the treating physician before code assignment.
Commonly Confused With
The main point of confusion is with beam radiation to the same body system, where the distinguishing feature is whether a source was implanted rather than aimed from outside the body. It is also sometimes conflated with transarterial radioembolization procedures involving radioactive microspheres, which may be captured differently depending on how the physician documents the delivery method and intent, making careful review of the procedure note essential.